Arcutis Biotherapeutics (ARQT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
22 Apr, 2026Executive summary
Annual Meeting scheduled for June 5, 2026, at 7:30 AM Pacific Time, with virtual participation available.
Shareholders are encouraged to review proxy materials and vote by June 4, 2026.
Voting matters and shareholder proposals
Election of three Class III directors to serve until the 2029 Annual Meeting or until successors are elected.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote to approve compensation of named executive officers.
Provision to transact other business as may properly come before the meeting.
Board of directors and corporate governance
Nominees for Class III director positions: Patrick J. Heron, Neha Krishnamohan, and Todd Franklin Watanabe.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Arcutis Biotherapeutics
- Expanding indications, pipeline progress, and strong financials drive growth outlook.ARQT
Goldman Sachs 46th Annual Global Healthcare Conference8 Jul 2026 - FDA approved ZORYVE Cream for atopic dermatitis, expanding access and demonstrating rapid efficacy.ARQT
FDA Announcement8 Jul 2026 - Q2 revenues surged 547% year-over-year, fueled by ZORYVE launches and improved coverage.ARQT
Q2 20248 Jul 2026 - Strong sales growth, new launches, and pediatric expansion drive momentum; cash flow positive by 2026.ARQT
H.C. Wainwright 27th Annual Global Investment Conference8 Jul 2026 - Strong growth, pipeline progress, and expanding market access drive ZORYVE's leadership.ARQT
Goldman Sachs 47th Annual Global Healthcare Conference 202610 Jun 2026 - All proposals, including director elections and auditor ratification, were approved.ARQT
AGM 20265 Jun 2026 - Q1 2026 revenue rose 65% to $105.4M, net loss narrowed, and cash reserves remained strong.ARQT
Q1 202612 May 2026 - Board recommends director elections, auditor ratification, and pay approval, with strong governance and ESG focus.ARQT
Proxy filing22 Apr 2026 - Raising 2026 revenue guidance, ZORYVE accelerates growth with new indications and expanded access.ARQT
25th Annual Needham Virtual Healthcare Conference14 Apr 2026